[go: up one dir, main page]

UY31708A - NEW REGIME OF DROSPIRENONA / 17B-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION - Google Patents

NEW REGIME OF DROSPIRENONA / 17B-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION

Info

Publication number
UY31708A
UY31708A UY0001031708A UY31708A UY31708A UY 31708 A UY31708 A UY 31708A UY 0001031708 A UY0001031708 A UY 0001031708A UY 31708 A UY31708 A UY 31708A UY 31708 A UY31708 A UY 31708A
Authority
UY
Uruguay
Prior art keywords
estradiol
phase
pharmaceutical product
drospirenona
kit
Prior art date
Application number
UY0001031708A
Other languages
Spanish (es)
Inventor
Dr Rolf Schuermann
Dr Vladimir Hanes
Dr Bernd Duesterberg
Dr Joachim Marr
Dr Hartmut Blode
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY31708A publication Critical patent/UY31708A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Producto farmacéutico combinado trifásico que comprende 24 unidades de dosificación diarias consecutivas en sus tres fases que comprende, en cada fase del producto trifásico, entre 6 y 10 unidades de dosificación diarias, en donde la cantidad de drospirenona en cada dosificación diaria de cada fase es la misma y está comprendida entre 1,5 y 3,0 mg, y la cantidad de 17B (beta)-estradiol aumenta de 1,0 mg en cada unidad de dosificación en la primera fase a una cantidad de 2,0 mg de 17B (beta)-estradiol en la tercera fase.Three-phase combined pharmaceutical product comprising 24 consecutive daily dosage units in its three phases comprising, in each phase of the three-phase product, between 6 and 10 daily dosage units, wherein the amount of drospirenone in each daily dosage of each phase is the same and is between 1.5 and 3.0 mg, and the amount of 17B (beta) -estradiol increases from 1.0 mg in each dosage unit in the first phase to an amount of 2.0 mg of 17B ( beta) -estradiol in the third phase.

UY0001031708A 2008-03-13 2009-03-13 NEW REGIME OF DROSPIRENONA / 17B-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION UY31708A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3612908P 2008-03-13 2008-03-13
US4041008P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
UY31708A true UY31708A (en) 2009-11-10

Family

ID=41665343

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031708A UY31708A (en) 2008-03-13 2009-03-13 NEW REGIME OF DROSPIRENONA / 17B-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION

Country Status (3)

Country Link
AR (1) AR072246A1 (en)
PE (1) PE20091626A1 (en)
UY (1) UY31708A (en)

Also Published As

Publication number Publication date
AR072246A1 (en) 2010-08-18
PE20091626A1 (en) 2009-11-22

Similar Documents

Publication Publication Date Title
CL2008001002A1 (en) COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
CL2008001003A1 (en) COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
MX2009010289A (en) COMPOSITIONS FOR NASAL ADMINISTRATION.
CL2008003393A1 (en) Compounds derived from imidazo [1,2-a] pyridine, allosteric modulators of mglur2 receptors; pharmaceutical composition comprising said compounds; and its use in the preparation of medicaments to treat disorders of the central nervous system.
EP2224973A4 (en) Preservatives for cosmetic, toiletry and pharmaceutical compositions
BR112012030818A2 (en) "modified c-3 betulinic acid derivatives as inhibitors of hiv maturation"
CL2014001158A1 (en) Alkylated piperazine derivative compounds; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; kit and use in the treatment of immune disorders, cancer, cardiovascular diseases, inflammation, among others.
MA38399A1 (en) Formulation in tablet form, useful for treating acute heart failure and chronic heart failure
NO20081038L (en) Pharmaceutical formulations / compositions of guanfacine suitable for daily single dosage form administration
BR112015018095A2 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2009009439A (en) Stabilization of vitamin b12.
UY31922A (en) COMPOUNDS
UY32187A (en) TOPIC PHARMACEUTICAL COMPOSITIONS
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
UY32650A (en) MEDICINAL ORAL ADMINISTRATION CONTAINING AT LEAST ONE STEROGEN AND / OR AT LEAST A GESTAGEN AND AT LEAST A PROBIOTIC BACTERIA CEPA
WO2013032558A3 (en) Products for anti-inflammation support
UY31010A1 (en) NEW REGIME OF DROSPIRENONA / 17B-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION
TR200903036A2 (en) Combinations of thiocolchicoside and non-steroidal anti-inflammatory drugs
UY31708A (en) NEW REGIME OF DROSPIRENONA / 17B-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION
BRPI1002067A8 (en) LEISHMANICIDAL FORMULATION AND ITS USE
PA8802001A1 (en) NOVEDOUS ANTIRETROVIRAL COMBINATION
ECSP099482A (en) PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS
UY31709A (en) NEW REGIME OF DROSPIRENONA / 17B (BETA) -ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION
CL2014001581A1 (en) Pharmaceutical combination comprising a) an antiepileptic selected from pregabalin or oxcarbazepine and b) vitamins selected from i) vitamin b12, ii) vitamin b1 and b12, with the exception of methylcobalamin and benfothiamine; pharmaceutical composition; and its use to treat or prevent moderate to severe pain; parts kit
CL2008002730A1 (en) DERMATOLOGICAL PHARMACEUTICAL COMPOSITION, OF TOPICAL APPLICATION, IN THE FORM OF A CREAM, GEL, Ointment, SOLUTION, EMULSION THAT INCLUDES 1A 99% OF PENTOXYPHILINE, 0.1 TO 80% OF BASE CREAM AND 0.1 to 75% OF LIPOSOMES, USEFUL FOR ROSACEA , DISORDERS WITH PHOTOSENSIBILE

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181017